利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.017 秒)

    Therapeutic agents II
    2.
    发明申请
    Therapeutic agents II 审中-公开
    治疗剂二

    公开(公告)号：US20070185119A1

    公开(公告)日：2007-08-09

    申请号：US10596995

    申请日：2005-01-05

    申请人： Emma Evertsson ,  Tord Inghardt ,  Jan Lindberg ,  Anna Linusson

    发明人： Emma Evertsson ,  Tord Inghardt ,  Jan Lindberg ,  Anna Linusson

    IPC分类号： A61K31/517 ,  C07D403/02 ,  C07D413/02

    CPC分类号： C07D409/12 ,  C07D239/95 ,  C07D401/12 ,  C07D403/12

    摘要： Compounds of Formula (I) as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.

    摘要翻译： 式（I）化合物及其旋光异构体及其外消旋物及其药学上可接受的盐，其制备方法，用于治疗肥胖症，精神疾病，认知障碍，记忆障碍，精神分裂症，癫痫， 和相关病症，以及诸如痴呆，多发性硬化症，帕金森病，亨廷顿氏舞蹈病和阿尔茨海默病以及疼痛相关疾病的神经障碍以及含有它们的药物组合物。

    Mchir antagonists
    4.
    发明申请
    Mchir antagonists 审中-公开

    公开(公告)号：US20060247439A1

    公开(公告)日：2006-11-02

    申请号：US10520372

    申请日：2003-07-04

    申请人： Asim Ray ,  Emma Evertsson ,  Anna Stina Linusson Jonsson ,  Pernilla Sandberg ,  Tord Ingiiardt ,  Anette Svensson ,  Kay Brickmann

    发明人： Asim Ray ,  Emma Evertsson ,  Anna Stina Linusson Jonsson ,  Pernilla Sandberg ,  Tord Ingiiardt ,  Anette Svensson ,  Kay Brickmann

    IPC分类号： A61K31/4709 ,  A61K31/4706 ,  C07D409/02 ,  C07D405/02 ,  C07D401/02

    CPC分类号： C07D215/38 ,  C07D401/12 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12

    摘要： The present invention provides compounds of formula (I), wherein R1 represents a C1-4 alkoxy group optionally substituted by one or more fluoro or a C1-4alkyl group optionally substituted by one or more fluoro; n represents 0 or 1; R2 represents a C1-4alkyl group optionally substituted by one or more fluoro or a C1-4alkoxy group optionally substituted by one or more fluoro; m represents 0 or 1; R3 represents H or a C1-4alkyl group; L1 represents an alkylene chain (CH2)r in which r represents 2 or 3 or L1 represents a cyclohexyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of the cyclohexyl group or L1 represents a cyclopentyl group wherein the two nitrogens bearing R3 and R4, respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group and additionally when R5 represents 9,10-methanoanthracen-9(10H)-yl the group -L1-N(R4)— together represents a piperidyl ring which is linked to L2 through the piperidinyl nitrogen and to N—R3 via the 4 position of the piperidyl ring with the proviso that when R5 represents 9,10-methanoanthracen-9(10H)-yl then r is only 2; R4 represents H or a C1-4alkyl group optionally substituted by one or more of the following: an aryl group or a heteroaryl group; L2 represents a bond or an alkylene chain (CH2), in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: a C1-4alkyl group, phenyl or heteroaryl; R5 represents aryl, a heterocyclic group or a CH3-8cycloalkyl group which is optionally fused to a phenyl or to a heteroaryl group; as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof; with provisos, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.